2025
Quality of gastrointestinal surgical oncology care according to insurance status
Butensky S, Kerekes D, Bakkila B, Billingsley K, Ahuja N, Johnson C, Khan S. Quality of gastrointestinal surgical oncology care according to insurance status. Journal Of Gastrointestinal Surgery 2025, 29: 101961. PMID: 39800081, DOI: 10.1016/j.gassur.2025.101961.Peer-Reviewed Original ResearchConceptsMedicare-insured patientsNational Cancer DatabaseAdequate lymphadenectomyNegative marginsCancer DatabaseRetrospective study of adult patientsStudy of adult patientsSurvival analysisInsurance statusReceipt of lymphadenectomyCurative-intent resectionGastrointestinal (GI) cancersIncreased risk of deathMultivariate survival analysisAdequacy of lymphadenectomyCox proportional hazards modelsRisk of deathProportional hazards modelResection marginsSurgical oncology careAdjuvant therapyRetrospective studyAdult patientsBiliary organismsLymphadenectomy
2024
BIOS-03. CLINICAL PRESENTATION, MANAGEMENT, AND OUTCOME IN NEUROLYMPHOMATOSIS: A SYSTEMATIC REVIEW AND ANALYSIS OF INDIVIDUAL PATIENT DATA FROM 459 CASES
Kaulen L, Hielscher T, Doubrovinskaia S, Hoffmann D, Kessler T, Traub B, Baehring J, Wick W. BIOS-03. CLINICAL PRESENTATION, MANAGEMENT, AND OUTCOME IN NEUROLYMPHOMATOSIS: A SYSTEMATIC REVIEW AND ANALYSIS OF INDIVIDUAL PATIENT DATA FROM 459 CASES. Neuro-Oncology 2024, 26: viii38-viii38. PMCID: PMC11552887, DOI: 10.1093/neuonc/noae165.0151.Peer-Reviewed Original ResearchPeripheral nervous systemPrimary NLPrognostic factorsDiagnostic yieldFDG-PETRituximab-based therapyRituximab-based treatmentMedian overall survivalNon-Hodgkin's lymphomaManifestation of malignancyNervous systemTumor-directed therapyMultivariate survival analysisCox proportional hazards modelsTreatment of NLConcurrent systemic diseaseSystematic reviewProportional hazards modelConsensus therapyPainful polyneuropathyLymphomatous infiltrationOverall survivalPerformance statusPrognostic stratificationClinical presentationThe Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART)
Chakrani Z, Patel M, Mellgard G, McCroskery S, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao C, Ganta T, Patel V. The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART). Clinical Genitourinary Cancer 2024, 22: 102227. PMID: 39437664, DOI: 10.1016/j.clgc.2024.102227.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen Receptor AntagonistsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMolecular Targeted TherapyProgression-Free SurvivalProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantReceptors, AndrogenRetrospective StudiesSurvival RateTreatment OutcomeConceptsMetastatic castration-resistant prostate cancerAndrogen receptor-targeted therapiesPSA progression free survivalOverall survivalConcurrent statinSurvival outcomesStatin useSingle-institution retrospective analysis of patientsHazard ratioSingle-institution retrospective analysisCastration-resistant prostate cancerRetrospective analysis of patientsConcurrent statin useAssociation of statin useProgression free survivalReceptor-targeted therapyCox proportional hazards regression modelsOutcomes of patientsAnalysis of patientsMultivariate survival analysisProportional hazards regression modelsTumor cell viabilityMultivariate logistic regressionHazards regression modelsEstimate hazard ratiosAnalysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival
Pereslete A, Hughes M, Martin A, Files J, Nguyen K, Buckley L, Patel A, Moore A, Winer E, Dillon D, Li T, Tolaney S, Lin N, Sammons S. Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival. Neuro-Oncology 2024, 27: 184-194. PMID: 39211994, PMCID: PMC11726339, DOI: 10.1093/neuonc/noae163.Peer-Reviewed Original ResearchHER2-low expressionHER2-lowMetastatic breast cancerHER2-positiveHER2 expressionHER2-0Primary tumorBrain metastasesEstrogen receptorBreast cancerHER2-positive primary tumorsASCO-CAP guidelinesNCI-designated centersMultivariate survival analysisCox proportional hazards modelsAntibody-drug conjugatesProportional hazards modelActive antibody-drug conjugateASCO-CAPHER2 gainHER2 statusInferior survivalOverall survivalIntracranial activityRetrospective analysisClinical Presentation, Management, and Outcome in Neurolymphomatosis
Kaulen L, Hielscher T, Doubrovinskaia S, Hoffmann D, Kessler T, Traub B, Baehring J, Wick W. Clinical Presentation, Management, and Outcome in Neurolymphomatosis. Neurology 2024, 103: e209698. PMID: 39102613, DOI: 10.1212/wnl.0000000000209698.Peer-Reviewed Original ResearchConceptsPeripheral nervous systemPrimary NLPrognostic factorsDiagnostic yieldFDG-PETMedian overall survivalRituximab-based therapyRituximab-based treatmentNon-Hodgkin's lymphomaManifestation of malignancyNervous systemLog-rank testTumor-directed therapyMultivariate survival analysisCox proportional hazards modelsTreatment of NLConcurrent systemic diseaseIndividual patient dataProportional hazards modelConsensus therapyPainful polyneuropathyLymphomatous infiltrationOverall survivalPerformance statusPrognostic stratification
2022
The prognostic significance of the circumferential resection margin in esophageal squamous cell carcinoma patients without neoadjuvant treatment
Yang Z, Lin H, Wang Z, Rong L, Zhang X, Wang L, Qin J, Xue X, Li Y, Xue L. The prognostic significance of the circumferential resection margin in esophageal squamous cell carcinoma patients without neoadjuvant treatment. BMC Cancer 2022, 22: 1180. PMID: 36384463, PMCID: PMC9670431, DOI: 10.1186/s12885-022-10276-1.Peer-Reviewed Original ResearchConceptsEsophageal squamous cell carcinomaEsophageal squamous cell carcinoma patientsRoyal College of Pathologists criteriaRoyal College of PathologistsCRM statusCollege of American PathologistsResection marginsPrognostic factorsPrognostic significancePrognostic valueSquamous cell carcinoma patientsLong-term prognostic significanceCircumferential resection marginCell carcinoma patientsCollege of American Pathologists criteriaSquamous cell carcinomaLymph node metastasisMultivariate survival analysisLong-term survivalPN0 subgroupPN3 subgroupsNeoadjuvant therapyNeoadjuvant treatmentPT3 tumorsTumor distance
2021
Outcomes of anus squamous cell carcinoma. Management of anus squamous cell carcinoma and recurrences
Marref I, Romain G, Jooste V, Vendrely V, Lopez A, Faivre J, Gerard J, Bouvier A, Lepage C. Outcomes of anus squamous cell carcinoma. Management of anus squamous cell carcinoma and recurrences. Digestive And Liver Disease 2021, 53: 1492-1498. PMID: 34193366, DOI: 10.1016/j.dld.2021.05.028.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaCell carcinomaAnal canalNet survivalBurgundy Digestive Cancer RegistryFive-year net survivalDigestive cancer registryCumulative recurrence ratePersistent active diseaseRisk of deathMultivariate survival analysisCumulative incidence functionCurative intentActive diseaseAbdominoperineal resectionAggressive managementCancer RegistryLocal inflammationRecurrence rateChemoradiotherapyCarcinomaRecurrenceRoutine practiceSurvival analysisRadiotherapy
2020
Tumor Location and Treatment Modality are Associated with Overall Survival in Adult Medulloblastoma
K A, Freedman I, Lee JH, Miyagishima D, Ahmed O, Yeung J. Tumor Location and Treatment Modality are Associated with Overall Survival in Adult Medulloblastoma. Cureus 2020, 12: e7061. PMID: 32226663, PMCID: PMC7089624, DOI: 10.7759/cureus.7061.Peer-Reviewed Original ResearchTumor locationOverall survivalAdult medulloblastomaPrognostic factorsAdult casesTreatment modalitiesSurvival timeMultivariate Cox proportional hazards modelWorse median survival timeCox proportional hazards modelOverall median survivalSignificant prognostic factorsBetter overall survivalEnd Results registryMedian survival timeMultivariate survival analysisUnited States SurveillanceProportional hazards modelCourse of treatmentAggressive brain tumorYears of ageMedian survivalSEER registryShorter survivalClinical variables
2019
Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization
Luo Y, Pandey A, Ghasabeh M, Pandey P, Varzaneh F, Zarghampour M, Khoshpouri P, Ameli S, Li Z, Hu D, Kamel I. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization. European Radiology 2019, 29: 5160-5171. PMID: 30877462, DOI: 10.1007/s00330-019-06100-3.Peer-Reviewed Original ResearchConceptsHepatic progression-free survivalTreated with transarterial chemoembolizationNeuroendocrine liver metastasesOverall survivalApparent diffusion coefficientTumor volumeMultiparametric MR imagingArterial enhancementVenous enhancementBaseline MR imagingMR imagingIndex lesionsTransarterial chemoembolizationPrognostic factorsPredicting OSPrognostic valueDominant lesionMean apparent diffusion coefficientAssociated with favorable OSProgression-free survivalLower tumor volumeMethodsThis retrospective studyMultivariate survival analysisEvaluation of multiple lesionsMR parameters
2018
Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial
Dahdaleh F, Sherman S, Poli E, Vigneswaran J, Polite B, Sharma M, Catenacci D, Maron S, Turaga K. Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. Surgery 2018, 164: 1223-1229. PMID: 30297240, DOI: 10.1016/j.surg.2018.06.044.Peer-Reviewed Original ResearchConceptsStage III colon cancerIII colon cancerDisease-free survivalColon cancerAdjuvant chemotherapyWorse survivalHistological gradeN stageCycles of adjuvant chemotherapyMedian follow-up timeAssociated with worse survivalChemotherapy-only armHigh-risk featuresAssociated with recurrenceKaplan-Meier methodIndependent risk factorCohort of patientsFollow-up timeMultivariate survival analysisCox proportional hazards modelsLong-term outcomesFisher's exact testRisk stratification modelBody mass indexProportional hazards modelPrognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes
Liao G, Hsu H, Chu C, Hong Z, Fu C, Chou Y, Golshan M, Dai M, Chen T, De-Chian C, Tsai W, Pan C, Hsu K, Kao E, Hsu Y, Chang T, Yu J. Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes. Journal Of Medical Sciences 2018, 38: 54-61. DOI: 10.4103/jmedsci.jmedsci_105_17.Peer-Reviewed Original ResearchRecurrent-free survivalBreast cancer subtypesLymph node statusLymphovascular invasionOverall survivalImportant prognostic factorLymph nodesPrognostic factorsHuman Investigation CommitteeLuminal HER2 subtypeNode statusHER2 subtypeBreast cancerSignificant differencesCancer subtypesLymph node involvementYear of diagnosisInstitutional review board approvalKaplan-Meier analysisTriple-negative subtypeMultivariate survival analysisCox proportional hazardsDate of deathReview board approvalSignificant independent relationship
2017
Temporal associations between prognostic indicators and overall survival after breast cancer.
Plichta J, Thomas S, Fayanju O, Rosenberger L, Park T, Hyslop T, Greenup R, Hwang E. Temporal associations between prognostic indicators and overall survival after breast cancer. Journal Of Clinical Oncology 2017, 35: e18144-e18144. DOI: 10.1200/jco.2017.35.15_suppl.e18144.Peer-Reviewed Original ResearchOverall survivalReduced overall survivalEndocrine therapyBreast cancerNon-metastatic invasive breast cancerAssociation of OSHormone receptorsTreatment factorsInvasive breast cancerLong-term outcomesInvasive ductal carcinomaMultivariate survival analysisUnderwent lumpectomyTerm outcomesDuctal carcinomaPrognostic indicatorMultiple time pointsBreast oncologistsSurvival analysisChemotherapyTime pointsTumorsCT/Temporal associationSurvival
2016
Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer
Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2016, 12: 314-322. PMID: 27720827, DOI: 10.1016/j.jtho.2016.09.122.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPneumonectomyPrognosisRetrospective StudiesSurvival RateTime FactorsConceptsNational Cancer Data BaseNeoadjuvant chemoradiationTiming of surgeryOverall survivalAdvanced non-small cell lung cancerNon-small cell lung cancerStage IIIA-N2 NSCLCStage IIIA NSCLCKaplan-Meier methodOverall survival rateSubset of patientsCell lung cancerLog-rank testMultivariate survival analysisProportional hazards modelIIIA NSCLCN2 NSCLCNeoadjuvant therapyTrimodality therapySurgical resectionClinical stageRetrospective studyLung cancerHazards modelSurvival rate
2014
Retrospective assessment of factors associated with readmission in a large psychiatric hospital in Guangzhou, China
Zhou Y, Rosenheck RA, Mohamed S, Fan N, Ning Y, He H. Retrospective assessment of factors associated with readmission in a large psychiatric hospital in Guangzhou, China. General Psychiatry 2014, 26: 138-148. PMID: 25114488, PMCID: PMC4118010, DOI: 10.3969/j.issn.1002-0829.2014.03.005.Peer-Reviewed Original ResearchLarge psychiatric hospitalIndex admissionReadmission ratesPsychiatric hospitalLarge public psychiatric hospitalPsychiatric inpatientsGuangzhou Psychiatric HospitalRate of readmissionRisk of readmissionPsychiatric inpatient admissionsLower readmission ratesCox regression modelLength of stayMultivariate survival analysisYear of dischargeMental health servicesInvoluntary psychiatric admissionsPublic psychiatric hospitalLonger admissionsMost patientsPrevious admissionsPrevious hospitalizationProspective studyInpatient admissionsPsychiatric admissions
2012
Is survival from resection of pancreatic adenocarcinoma with major arterial involvement any different than venous/minor arterial resection?
Miura J, Pappas S, Gamblin T, Turaga K. Is survival from resection of pancreatic adenocarcinoma with major arterial involvement any different than venous/minor arterial resection? Journal Of Clinical Oncology 2012, 30: 310-310. DOI: 10.1200/jco.2012.30.4_suppl.310.Peer-Reviewed Original ResearchArtery involvementPancreatic adenocarcinomaVenous resectionArtery resectionMedian disease specific survivalResection of pancreatic adenocarcinomaContraindication to resectionDisease specific survivalMultivariate survival analysisCox proportional hazards modelsT4-PAT4 diseaseSpecific survivalSurgical resectionPancreatic resectionSEER databaseRecommended surgeryCeliac axisLonger survivalResectionPoor survivalControl arm (CAAdenocarcinomaSurvival analysisHazards model
2011
Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma
Gupta D, Gunter MJ, Yang K, Lee S, Zuckerwise L, Chen LM, Goldberg GL, Huang GS. Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma. International Journal Of Gynecological Cancer 2011, 21: 529-534. PMID: 21436701, DOI: 10.1097/igc.0b013e31821091b5.Peer-Reviewed Original ResearchConceptsUterine papillary serous carcinomaPapillary serous carcinomaCA125 levelsLymph node metastasisDisease recurrenceCA125 elevationMetastatic diseaseNode metastasisSerum CA125Serous carcinomaStage III/IV diseaseCox proportional hazards regression modelingProportional hazards regression modelingElevated CA125 levelsPreoperative CA125 levelsLymph node involvementRecurrence-free survivalAdvanced International FederationMultivariate survival analysisUPSC patientsMean followSurgical stagingCA125 measurementNode involvementIndependent predictors
2009
Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis
Kountourakis P, Psyrri A, Scorilas A, Markakis S, Kowalski D, Camp RL, Diamandis EP, Dimopoulos MA. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thrombosis And Haemostasis 2009, 101: 541-546. PMID: 19277417, DOI: 10.1160/th08-01-0052.Peer-Reviewed Original ResearchConceptsProgression-free survivalOvarian cancerPrognostic significanceSurvival analysisFive-year overall survivalPlatinum-paclitaxel combination chemotherapyYear progression-free survivalAdvanced stage ovarian cancerAdvanced ovarian cancerStage ovarian cancerMultivariate survival analysisUnivariate survival analysisImportant prognostic biomarkerSerine protease enzyme familyExpression levelsSignificant correlationWarrants further investigationProtein expression levelsKLK8 expressionClinical responseOverall survivalSurgical debulkingCombination chemotherapyPrognostic valueResidual disease
2008
Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA)
Kountourakis P, Psyrri A, Scorilas A, Camp R, Markakis S, Kowalski D, Diamandis EP, Dimopoulos MA. Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). Cancer Science 2008, 99: 2224-2229. PMID: 18957059, PMCID: PMC11159123, DOI: 10.1111/j.1349-7006.2008.00942.x.Peer-Reviewed Original ResearchConceptsOvarian cancerOverall survivalPrognostic valueKLK6 expressionSurvival analysisPlatinum-paclitaxel combination chemotherapyAdvanced stage ovarian cancerAdvanced ovarian cancerProgression-free survivalProtein expressionStage ovarian cancerInferior patient outcomesUnivariate survival analysisMultivariate survival analysisImportant prognostic biomarkerSerine protease enzyme familyExpression levelsProtein expression levelsSurgical debulkingCombination chemotherapyPatient outcomesPrognostic biomarkerPrognostic variablesSufficient tissueTherapeutic targetHuman tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression
Psyrri A, Kountourakis P, Scorilas A, Markakis S, Camp R, Diamandis E, Dimopoulos M, Kowalski D. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Annals Of Oncology 2008, 19: 1271-1277. PMID: 18325919, DOI: 10.1093/annonc/mdn035.Peer-Reviewed Original ResearchConceptsOvarian cancerOverall survivalProtein expressionSurvival analysisPlatinum-paclitaxel combination chemotherapyAdvanced stage ovarian cancerAdvanced ovarian carcinomaDisease-free survivalPromising prognostic factorInferior patient outcomesMultivariate survival analysisUnivariate survival analysisImportant prognostic biomarkerSerine protease enzyme familyKallikrein 7Surgical debulkingCombination chemotherapyPrognostic factorsPrognostic valueOvarian carcinomaPatient outcomesPrognostic biomarkerPrognostic variablesNovel biomarkersBetter outcomes
2007
Evaluation of the prognostic significance of human kallikrein 8 protein expression levels in advanced ovarian cancer by using automated quantitative protein analysis
Kountourakis P, Psyrri A, Scorilas A, Markakis S, Kowalski D, Camp R, Diamandis E, Dimopoulos M. Evaluation of the prognostic significance of human kallikrein 8 protein expression levels in advanced ovarian cancer by using automated quantitative protein analysis. Journal Of Clinical Oncology 2007, 25: 5581-5581. DOI: 10.1200/jco.2007.25.18_suppl.5581.Peer-Reviewed Original ResearchOvarian cancerProtein expression levelsPrognostic significanceSurvival analysisPlatinum-paclitaxel combination chemotherapyYear progression-free survivalAdvanced stage ovarian cancerExpression levelsProgression-free survivalAdvanced ovarian cancerAdverse prognostic factorDisease-free survivalStage ovarian cancerUnivariate survival analysisMultivariate survival analysisKallikrein-8Important prognostic biomarkerSerine protease enzyme familyFree survivalSurgical debulkingCombination chemotherapyPrognostic factorsPrognostic valueResidual diseaseClinicopathological variables
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply